CooperCompanies stock steadies as investors digest June quarter beat
Published on 08/28/2026 at 20:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CooperCompanies (US21664P1039) stock is trading at $72.68 with a market value of $14.17 billion as of August 27, 2026, leaving the shares positioned close to the middle of their 52-week range from $58.89 to $89.83 per recent market data.
The medical device maker recently reported June 4, 2026 quarter revenue of $1.08 billion and earnings of $1.21 per share, both ahead of the $1.05 billion and $1.10 estimates cited in the same earnings overview, giving investors a concrete signal that fundamentals are tracking ahead of expectations.
On a year-over-year basis, that June quarter revenue advanced 7.9% and EPS increased from $0.96 a year earlier to $1.21, underscoring how margin progress is contributing to earnings growth alongside steady top-line expansion.
June quarter beat shapes current earnings picture
Per an earnings summary published on August 27, 2026, CooperCompanies delivered June 4, 2026 quarter revenue of $1.08 billion versus consensus expectations of $1.05 billion, a positive gap of $30 million that reflects firm demand across its core contact lens and women’s health franchises.
The same snapshot shows diluted EPS at $1.21 for the June quarter compared with a $1.10 market estimate, a $0.11 beat that suggests operating leverage and mix helped earnings outpace modest revenue growth.
Relative to the prior-year June quarter, revenue grew 7.9% while EPS climbed from $0.96 to $1.21, implying that profit rose faster than sales as CooperCompanies continued to work on cost efficiency and product mix.
For investors, the combination of a clear revenue beat and a larger EPS beat matters because it indicates that the company is not only growing its top line but also converting that growth into better profitability, an important signal in the current medical device landscape where pricing and input costs are under scrutiny.
Valuation context and trading range
The same August 27, 2026 market snapshot places CooperCompanies shares at $72.68, equating to a $14.17 billion market capitalization, and within a 52-week range stretching from $58.89 on the low end to $89.83 at the high.
With the current price closer to the midpoint of that band than to either the 52-week high or low, the market is signaling a balanced view after the June quarter beat, neither chasing the shares to their recent peak nor discounting them back toward last year’s trough.
Investors can interpret that positioning as a sign that the recent earnings strength is largely embedded in the valuation while leaving room for future moves if upcoming quarters show either accelerating growth or a moderation in the current trend.
In addition, the next scheduled earnings communication is noted for September 9, 2026 in the same overview, creating a clear near-term catalyst date when the company is expected to update its outlook and report subsequent quarterly figures.
Contact lens and women’s health portfolio as growth drivers
CooperCompanies is best known for its broad portfolio of specialty contact lenses and related eye care products, together with a growing women’s health business that spans fertility and contraception solutions.
In practice, the contact lens segment benefits from recurring demand as patients replace lenses on a regular schedule, which tends to support stable revenue streams and offers a platform for incremental innovation such as higher oxygen-permeable materials or lenses designed for specific vision issues.
The women’s health portfolio provides diversification beyond eye care, giving CooperCompanies exposure to procedures and products tied to fertility, gynecological health, and family planning, areas where demographics and access to care can support long-term volume growth.
For shareholders, this mix of a recurring lens business and a more episodic but structurally supported women’s health line creates a company profile that combines defensive characteristics with selective growth, helping contextualize why the June quarter numbers and the upcoming September 9, 2026 earnings date attract close attention.
Shares trade in the low-$70s range
As of August 27, 2026, CooperCompanies trades at $72.68 in regular Nasdaq dealings, a level that implies investors are willing to pay a mid-range price against the stock’s 52-week history while monitoring whether the recent pattern of high single-digit revenue growth and faster EPS expansion can continue.
The June 4, 2026 quarter revenue of $1.08 billion, compared with $1.00 billion a year earlier, and EPS of $1.21 versus $0.96 over the same span, show how the business has added $80 million in quarterly sales and $0.25 in quarterly earnings per share year over year, a concrete improvement that underpins the current valuation.
Looking to the next few weeks, the September 9, 2026 earnings date will likely serve as the next key checkpoint for CooperCompanies stock, when investors will see whether the company can sustain or improve on that $30 million revenue beat and $0.11 EPS outperformance relative to expectations.
Read more
More on CooperCompanies stock
Representative product context
Within its eye care franchise, CooperCompanies markets a range of silicone hydrogel contact lenses intended to provide high oxygen transmission for comfort while supporting different wearing schedules and vision correction needs.
These lenses are typically offered in daily, two-week, or monthly replacement cycles, allowing eye care providers to match products to patient lifestyles and prescription requirements while contributing to the recurring revenue pattern that helps support the company’s quarterly figures.
From an investment perspective, such products illustrate how incremental improvements in materials and design can translate into higher-value offerings that support both volume and pricing, factors that investors watch closely when assessing the sustainability of the revenue growth and EPS progression seen in the June 4, 2026 quarter.
CooperCompanies stock and current market level
CooperCompanies stock at $72.68 as of August 27, 2026, with a $14.17 billion market cap and a 52-week range from $58.89 to $89.83, offers a snapshot of how the market currently balances solid recent earnings beats against the broader medical device sector backdrop.
Fact box
Company: CooperCompanies Inc.
ISIN: US21664P1039
Ticker: COO
Exchange: Nasdaq
Price (as of August 27, 2026, 4:00 p.m. ET): $72.68 USD
Market cap: $14.17 billion (as of August 27, 2026)
Sector / Industry: Health care - Medical devices
Index membership: S&P 500
Next earnings date: September 9, 2026
